Down 27% in 4 Weeks, Here's Why Adma Biologics (ADMA) Looks Ripe for a Turnaround

Adma Biologics (ADMA) is technically in oversold territory after heavy selling and may be set up for a trend reversal. Broad, coordinated upward revisions to earnings estimates by Wall Street analysts bolster the bullish case and raise the likelihood of a near-term positive re-rating of the stock.

Analysis

Adma Biologics (ADMA) is technically in oversold territory after heavy selling and may be set up for a trend reversal. Broad, coordinated upward revisions to earnings estimates by Wall Street analysts bolster the bullish case and raise the likelihood of a near-term positive re-rating of the stock.